Plain-English translation of NCT07602777 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer drug called Risvutatug Rezetecan to see if it can help people with advanced bone cancer (osteosarcoma) or soft tissue sarcoma that has come back or spread after earlier treatment. Researchers want to learn whether the medication is safe, how well patients tolerate it, and how well it works against these cancers.
People with advanced sarcomas that return after initial treatment have limited options and a poor outlook. This medication represents a new approach to fighting these cancers, and this trial is designed to see if it can offer hope to patients who have already tried other treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic regularly to receive the new medication and have blood work and imaging tests to monitor how the cancer responds and how your body handles the drug. Depending on which group you are assigned to, you may receive the medication alone or combined with a supportive medication to help protect your blood cells. The study is designed to carefully track your health, any side effects, and whether the cancer improves over time.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States
Canada
France